Imugene Limited (IMU.AX)

AUD 0.02

(-7.69%)

Market Cap (In AUD)

179.16 Million

Revenue (In AUD)

-

Net Income (In AUD)

-149.68 Million

Avg. Volume

20.71 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.035-0.13
PE
-1.2
EPS
-0.02
Beta Value
3.34
ISIN
AU000000IMU9
CUSIP
Q48850103
CIK
-
Shares
7465390000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Leslie Chong
Employee Count
-
Website
https://www.imugene.com
Ipo Date
1998-12-31
Details
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.